Pathology Diagnostics Ltd (PDL) Wins Prestigious Biomedical Catalyst (BMC) Scheme Award

Cambridge, United Kingdom, September 12, 2014 --(PR.com)-- Pathology Diagnostics Ltd is one of the earliest SME recipients of the £180 million Technology Strategy Board (the UK’s Innovation Agency) Biomedical Catalyst funding programme; winning a Biomedical Catalyst feasibility award in the second round of the BMC scheme in December 2012. The initiative was set-up by the UK government in 2012 to provide responsive and effective support for the best life science opportunities arising across the nation. Pathology Diagnostics Ltd. is merging advances in computer imaging and other digital technologies with traditional pathology techniques to develop point of care diagnostic applications that will provide more accurate quantitative tissue based testing in the clinic. This builds on the technical and innovative strength and expertise of the company’s current scientific portfolio. Commenting on the award and the project that led to it being won, Managing Director of Pathology Diagnostics Dr. Madhuri Warren said: “We are very proud to have been awarded this TSB grant which is one of a number of European grants that we have been awarded to develop biomarker & diagnostics research with commercial and academic partners. The employees at Pathology Diagnostics worked hard and were highly successful in delivering this project on time and within budget constraints. We will be using the feasibility study data to develop our future exploitation plan. Our aim is to find new SME collaborative partners and follow on grant and commercial funding to develop the technical prototype to a product you will be able to see on the market.”

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy.

Notes to editors and media:
Pathology Diagnostics Ltd is an independent GCLP accredited UK research SME engaged in innovative healthcare and pharmaceutical research. We also deliver high-quality tissue laboratory & diagnostics to industry Research & Development scientists engaged in drug and biomarker development. Specialising in the provision of clinical diagnostics and quantitative image analysis on human tissues for studies ranging from early discovery to clinical trials, Pathology Diagnostics has a wide range of technical capabilities from traditional histopathology techniques to advanced digital pathology, whole slide scanning, central biorepository services and quantitative image analysis of biomarkers.